A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque or Active Psoriatic Arthritis in India

PHASE4CompletedINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

June 27, 2023

Primary Completion Date

August 8, 2024

Study Completion Date

September 23, 2024

Conditions
Plaque PsoriasisPsoriatic Arthritis
Interventions
DRUG

Ixekizumab

Administered SC

Trial Locations (14)

160012

Postgraduate Institute of Medical Education & Research, Chandigarh

380006

V.S. General Hospital, Ahmedabad

380015

Amber Clinic, Ahmedabad

380016

B. J. Medical College & Civil Hospital, Ahmedabad

380060

GMERS Medical College & Hospital, Ahmedabad

395001

Tristar Hospital, Surat

400706

Dr. D. Y. Patil Medical College & Hospital, Navi Mumbai

411001

Grant Medical Foundation - Ruby Hall Clinic, Pune

411005

Oyster & Pearl Hospitals (Phadnis Clinic Pvt. Ltd.), Pune

492099

All India Institute of Medical Sciences, Raipur

530002

King George Hospital, Vizag

575002

Father Muller Medical College Hospital, Mangalore

700017

Wizderm Specialty Skin And Hair Clinic, Kolkata

700073

Medical College & Hospital, Kolkata

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT05855967 - A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque or Active Psoriatic Arthritis in India | Biotech Hunter | Biotech Hunter